RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company’s web site at www.rxipharma.com.
- 17 years ago
QualityStocks
RXi Pharmaceuticals Corp. (NASDAQ: RXII)
Related Post
-
QualityStocksNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
As the rise of AI-generated services places extreme pressure on the global power grid, Platinum Group…
-
QualityStocksNewsBreaks – Spotlight on ONAR Holding Corp.’s (ONAR) Strategic Playbook: AI-Optimized Campaigns
ONAR (OTCQB: ONAR) was featured in a recent article that discussed its strategy amid the AI…
-
QualityStocksNewsBreaks – Why AI Maverick Intel Inc. (BINP) Is ‘One to Watch’
AI Maverick Intel (OTCID: BINP) recently rebranded and adopted a new strategic direction focused on…